Literature DB >> 20362199

Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization.

P V Licciardi1, A Balloch, F M Russell, E K Mulholland, M L K Tang.   

Abstract

Cross-reactivity within the pneumococcal immune response was examined in this study. Significant cross-reactivity between serotypes 9V, 15B and 19A was identified in infant post-immunization serum that could not be effectively titrated during specific IgG measurements. Pre-absorption using serotype 9V inhibited this cross-reactivity and normalized titratability in the WHO ELISA for serotypes 15B and 19A. However, this did not affect functional avid IgG and was associated with fewer pneumococcal conjugate vaccine (PCV) doses, suggesting that cross-reactive antibodies were of low avidity. The results in this study have important implications for assessment of vaccine immunogenicity. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362199     DOI: 10.1016/j.vaccine.2010.03.033

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi L K Tang
Journal:  J Allergy Clin Immunol       Date:  2012-02-02       Impact factor: 10.793

2.  Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.

Authors:  F M Russell; A Balloch; P V Licciardi; J R Carapetis; L Tikoduadua; L Waqatakirewa; Y B Cheung; E K Mulholland; M L K Tang
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

3.  Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.

Authors:  H Schaballie; G Wuyts; D Dillaerts; G Frans; L Moens; M Proesmans; F Vermeulen; K De Boeck; I Meyts; X Bossuyt
Journal:  Clin Exp Immunol       Date:  2016-05-20       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.